Filings (90d)
Other insiders active in the same sector
No other insider has filed at Helen K. Ellias's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Jesse J. Geiger - $41.11M in MEDP purchases and sales in the last 12 months
- Mark Hancock - $40.97M in PACS purchases and sales in the last 12 months
- EcoR1 Capital, LLC - $40.00M in AKTS purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $40.00M in BCAX purchases and sales in the last 12 months
- Sanj K. Patel - $39.43M in KNSA purchases and sales in the last 12 months
- Hellman & Friedman Capital Partners X (Parallel), L.P. - $2.65B in MDLN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Helen K. Ellias?
Helen K. Ellias is a corporate insider of SAB Biotherapeutics, Inc. (SABS). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Helen K. Ellias last file a Form 4?
The most recent primary Form 4 on record is dated 18 December 2025, one of 2 filings going back to 2024.